This Biotech Stock Is Soaring Today On Positive Trial Results

• The study found that patients maintained strong treatment responses with dosing every 3 or 6 months.
• The drug also showed continued improvement in skin lesions and itch symptoms across the full study population, Apogee said.
• The biotech firm added that results from Part B of its APEX trial are expected in the second quarter of fiscal 2026.

Shares of Apogee Therapeutics (APGE) popped 18% in pre-market trading on Monday after the biotech firm said its lead drug, Zumilokibart, showed positive 52-week maintenance results in a Phase 2 trial for patients with moderate-to-severe Atopic Dermatitis, a type of skin condition.

The study found that patients maintained strong treatment responses with dosing every 3 or 6 months, suggesting the therapy could require less frequent dosing than current options.

Among patients who responded by Week 16, 75% on three-month dosing and 85% on six-month dosing maintained at least a 75% reduction in EASI scores. The drug also showed continued improvement in skin lesions and itch symptoms across the full study population. The therapy was generally well tolerated, with common side effects including conjunctivitis and upper respiratory infections, Apogee said.

“Consistent maintenance of response as well as deepening of responses over time were observed across key endpoints for both the 3- and 6-month dosing regimens, demonstrating a highly differentiated profile that could allow treatment to be administered as few as two times per year, compared with up to 26 injections annually for currently available therapies,” said Carl Dambkowski, Chief Medical Officer of Apogee.

Part B Of Phase 2 Study Expected In Q2 2026

Apogee said that Part B of its APEX trial is a placebo-controlled study evaluating different doses of Zumilokibart, with 347 patients split across high, medium, low, and placebo groups. Results from the 16-week study are expected in the second quarter of 2026, earlier than the company’s initial timeline of the second half of the year.

Based on the current findings and regulatory progress, the company aims to start Phase 3 trials in the second half of 2026, with a potential launch targeted for 2029.

How Did Stockwits Users React?

Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.

One user highlighted that for biotech stocks, clearing a coil squeeze could mean a sharp upside.

More than 2 million shares changed at the time of writing, more than twice the average volumes of 0.8 million, according to Stocktwits data.

Another user said that despite the stock doubling in value over the past year, it is only the “beginning.”

Year-to-date, the stock has climbed around 6%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.